Novo Nordisk SWOT Analysis, Competitors, Segmentation, Target Market, Positioning & USP

Novo Nordisk

Pharmaceutical

Pharma and Healthcare

Changing diabetes

It is leading healthcare company with experience in diabetes treatment &  considerable experience in other area also

Diabetes, homeostasis management & hormone replacement therapy

Endocrinologists, healthcare professionals providing treatment to patients suffering from diabetes  & other hormonal disorders

Novo Nordisk is leading healthcare company with more than 89 years of experience in diabetes treatment.

Below are the Strengths in the SWOT Analysis of Novo Nordisk:

1. Deep knowledge about diabetes & experience in its treatment

2. Free cash flow can be used for expansion, acquisition or R&D

3. Around 33,000 well trained employees in 75 countries

4. Wide global footprint  (present in 190 countries)

5. great diversity in senior management teams which is requisite for growth
6. It was awarded as the most sustainable company in the world

Here are the weaknesses in the Novo Nordisk SWOT Analysis:

1. Company suffered negative brand image due to its failure to provide information about side effects of Victoza.

2. Past legal actions have created negative image for company

Following are the Opportunities in Novo Nordisk SWOT Analysis:

1. Increasing prevalence of diabetes & other chronic ailments due to increasing urbanization & average life expectancy

2.  Biosimiler market has strong growth opportunities

3.  Growing numbers of health conscious people

The threats in the SWOT Analysis of Novo Nordisk are as mentioned:

1. Increasing public debt in European countries

2. Negative consequences of healthcare reforms in major markets

3. Stringent healthcare regulations

4. Increasing pressure in public spending on healthcare due to economic slowdown

Below are the top 4 Novo Nordisk competitors:

1. Eli Lilly
2. AstraZeneca

3. Biocon

4. Abbott Laboratories